[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"substance-abuse-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:substance-abuse-disorder":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,75,111,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100590009","the-effect-of-inspiratory-muscle-training-with-substance-use-disorder-100590009",false,"NCT06961838","The Effect of Inspiratory Muscle Training With Substance Use Disorder","Inclusion Criteria:\n\n* Being older than 18 years\n\n  * Meeting the current Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for Substance Use Disorder\n  * Receiving inpatient treatment\n  * Substance use for more than one year\n  * Being able to follow simple instructions\n  * Not having any visual and auditory pathology\n  * Being able to cooperate with the devices used.\n\nExclusion Criteria:\n\n* Failure to comply with the treatment and assessment program\n* Participation in a structured physiotherapy\u002Fexercise program in the last 6 months\n* Presence of current psychotic symptoms\n* Presence of any physical disability or medical problem\n* Presence of respiratory system problems such as asthma and tuberculosis and infectious health problems (e.g. HIV, hepatitis B).","ALL","18 Years",{"count":18,"type":19},34,"ESTIMATED","INTERVENTIONAL",[22],"NA","The aim was to investigate the effectiveness of inspiratory muscle training on dyspnoea, pulmonary function, respiratory muscle strength, cough capacity, functional exercise capacity, substance craving, depression, anxiety and quality of life in individuals with substance use disorder.",[25,26,27,28],"Substance Abuse Disorder","Exercise","Pulmonary Function","Rehabilitation",[30,26,28,27,31],"Substance Use Disorder","Muscle Training","RECRUITING","2026-04-28",{"date":35,"type":36},"2026-05-05","ACTUAL",{"date":38,"type":36},"2025-07-03",{"date":40,"type":19},"2026-07-01",{"name":42,"class":43},"Uskudar University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":16,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100577172","jomcare-study---a-harm-reduction-study-100577172","NCT06794840","JomCare Study - A Harm Reduction Study","Optimizing a Just-in-Time Adaptive Intervention to Increase Uptake of Chemsex Harm Reduction Services in MSM: A Micro-randomized Trial","JomCare","Inclusion Criteria:\n\n* Age ≥18 years;\n* Cisgender man;\n* HIV-negative or HIV status unknown;\n* Having engaged in \"chemsex\" in the past 12 months (defined as using CAD, including crystal methamphetamine, mephedrone, GBL\u002FGHB, and\u002For ecstasy\u002FMDMA)\n* Own a smartphone\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Enrolled in drug rehabilitation, substance use treatment, and narcotics or other behavioral intervention-based treatment\n* Unable to read and understand English or Bahasa Malaysia",true,"MALE",{"count":56,"type":19},482,[22],"Chemsex, the use of psychoactive drugs before or during sexual activity, is a growing public health concern associated with striking increases in HIV, particularly among men who have sex with men (MSM). This study proposes to optimize an app-based just-in-time adaptive intervention, called JomCare, which aims to reduce chemsex risk by delivering tailored support when a person is most likely to be vulnerable to chemsex risk behaviors and receptive to intervention, with the purpose of reducing risk and averting new HIV infections.",[60,25],"HIV",[60,62,63,64],"mHealth","JITAI","Chemsex","NOT_YET_RECRUITING","2026-02-20",{"date":68,"type":36},"2026-02-23",{"date":70,"type":19},"2026-04-01",{"date":72,"type":19},"2029-05-30",{"name":74,"class":43},"University of Connecticut",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":53,"sex":15,"minAge":16,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":20,"phases":85,"briefSummary":86,"conditions":87,"keywords":94,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":44},"100625026","lifus-for-neurological-disorders-100625026","NCT07417280","LIFUS For Neurological Disorders","Clinical Effects of Low-Intensity Focused Ultrasound Neuromodulation in Patients With Neurological and Psychiatric Disorders","Inclusion Criteria:\n\n* 18-85 years of age\n* Patients diagnosed with neurological disorders, (such as epilepsy, brain tumour, movement disorders) or psychiatric disorders (such as substance abuse disorder)\n* Patients undergoing medical or surgical treatment (such as DBS) for neurological disorders\n\nExclusion Criteria:\n\n* History of stroke\n* Comorbid dementia\n* Scored below 22 on the Montreal Cognitive Assessment (MoCA)\n* Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD)\n* Presence of metal implanted in body that is contraindicated in TMS\u002FMRI\n* Pregnancy\n* Major depression\u002Fpsychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study\n* Receiving a psychotropic medication or taking recreational substances that in the opinion of the investigator will significantly affect safety of the protocol\n* Major systemic illness or infection","85 Years",{"count":84,"type":19},50,[22],"Low intensity focused ultrasound (LIFUS) has the potential to be used as a means of non-invasive neuro-modulation. To this day, the use of LIFUS is under investigation. Studies in healthy subjects have shown that application of LIFUS to the motor region of the brain can mildly decrease neuron excitability in healthy controls. The purpose of the present study is to evaluate the effects of LIFUS on brain tissue excitability in patients with movement disorders in order to elucidate the therapeutic potential of LIFUS.",[88,89,90,91,92,25,93],"Parkinson's Disease (PD)","Essential Tremor","Orthostatic Tremor","Dystonia","Epilepsy","Deep Brain Stimulation",[95,89,90,91,92,25,93,96,30,97,98,99,100,101],"Parkinson's Disease","DBS","SUD","PD","LIFUS","Low-Intensity Focused Ultrasound","Neuromodulation","2026-02-10",{"date":104,"type":36},"2026-02-18",{"date":106,"type":36},"2025-12-02",{"date":108,"type":19},"2040-12-31",{"name":110,"class":43},"University Health Network, Toronto",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":53,"sex":15,"minAge":16,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":128,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100623347","assessments-of-obsessive-compulsive-symptoms-in-patients-with-substances-use-disorder-100623347","NCT07395453","Assessments of Obsessive-compulsive Symptoms in Patients With Substances Use Disorder","Assessments of Obsessive-compulsive Symptoms in Patients With Substances Use Disorder and Its Correlates","Inclusion Criteria:\n\n--Adults aged 18-50 years.\n\n* Willing and able to provide informed consent and participate in the study assessments.\n* For the case group: patients with a diagnosed substance use disorder (single or polysubstance) attending the inpatient or outpatient addiction management unit at the Neuropsychiatry Department, Assiut University Hospital.\n* For the control group: relatives, friends, or hospital workers without substance use disorder, recruited through invitation or advertisement.\n\nExclusion Criteria:\n\n* Severe psychiatric comorbidities such as schizophrenia, major depressive disorder, bipolar disorder, or anorexia nervosa.\n* Current intoxication or acute withdrawal state from substances.\n* Severe medical conditions including end-stage renal disease, metastatic cancer, severe heart failure, or chronic obstructive pulmonary disease.\n* Severe cognitive impairment","50 Years",{"count":120,"type":19},102,"OBSERVATIONAL","This observational, cross-sectional case-control study evaluates obsessive-compulsive symptoms among adults with substance use disorder compared with a demographically similar control group without substance use disorder. Patients aged 18-50 years attending the addiction management inpatient and outpatient services at Assiut University Hospital, and healthy controls recruited from relatives, friends, and hospital staff, will complete structured clinical interviews, the Yale-Brown Obsessive-Compulsive Scale, and other standardized scales for psychiatric symptoms, cognition, and quality of life. The main objective is to estimate the prevalence and severity of obsessive-compulsive symptoms in substance use disorder and examine their associations with sociodemographic and clinical factors, addiction severity, and quality of life in the recovery stage.",[124,125,126,25,127],"Obsessive - Compulsive Disorder","Obsessive Compulsive Disorder (OCD)","Obsessive Compulsive Behavior","Substance Use",[129,130],"obsessive-compulsive symptoms","substances use disorder","2026-02-01",{"date":133,"type":36},"2026-02-09",{"date":135,"type":19},"2026-03",{"date":137,"type":19},"2027-04",{"name":139,"class":43},"Assiut University",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":44},"100506975","examining-clinical-research-participation-for-substance-abuse-disorder-patient-100506975","NCT05881369","Examining Clinical Research Participation for Substance Abuse Disorder Patient","Exploring the Clinical Trial Journey of Patients in Substance Abuse Disorder Clinical Trials","Inclusion Criteria:\n\n* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.\n* Participant has a diagnosis of substance abuse disorder.\n* Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.\n\nExclusion Criteria:\n\n* Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.\n* Pregnant or lactating woman\n* Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results",{"count":148,"type":19},500,"Clinical study participation percentages haven't always been fully representative of a given demographic.\n\nThe goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through.\n\nThe data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future substance abuse disorder patients during clinical trials.",[25],[152],"substance abuse disorder","2023-05-19",{"date":155,"type":36},"2023-05-31",{"date":157,"type":19},"2024-06",{"date":159,"type":19},"2026-06",{"name":161,"class":162},"Power Life Sciences Inc.","INDUSTRY"]